A Phase 4 interventional study of placebo and varenicline tartrate in Smoking Cessation, sponsored by Pfizer. Completed at 134 sites in 16 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-29.
Sponsored by Pfizer · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 2nd largest by enrollment, is one of 6 that started in 2012, is one of 47 in phase 4, and was the 66th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,595 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 2nd largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2012, is one of 11 in phase 4, and was the 42nd registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.
This study is an extension protocol for study A3051123. No treatment is provided during this study. This study is to monitor for cardiovascular events 28 weeks after completion of A3051123. This study is an extension protocol for study A3051123. No treatment is provided during this study. This study is to monitor for cardiovascular events 28 weeks after completion of A3051123.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: placebo
Drug: varenicline tartrate
Drug: bupropion hydrochloride
Drug: Nicotine Replacement Therapy Patch
All dosing to have taken place per study A3051123
All dosing to have taken place per study A3051123
Also known as: Chantix; Champix
All dosing to have taken place per study A3051123
Also known as: Zyban
All dosing to have taken place per study A3051123
Also known as: NRT
Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.
Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.
Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.
Time to MACE Until the End of Study NCT01574703.
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.
Time frame: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).
Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.
Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.
Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.
Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
Incidence of MACE Assessed Until End of Study NCT01574703.
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.
Time frame: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Incidence of MACE+ Assessed Until End of Study NCT01574703.
This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.
Time frame: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Of the 6293 participants who completed the parent study NCT01456936 as per protocol, a total of 4595 participants enrolled into this study NCT01574703 from 132 centers in 16 countries.
| Milestone | Varenicline | Bupropion | Nicotine Replacement Therapy (NRT) Patch | Placebo |
|---|---|---|---|---|
| Started | 1192 | 1166 | 1116 | 1121 |
| Completed | 1067 | 1054 | 1011 | 1007 |
| Not completed | 125 | 112 | 105 | 114 |
| Withdrew: Adverse event | 0 | 2 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Unspecified reason | 27 | 15 | 20 | 16 |
| Withdrew: Withdrawal by subject | 53 | 52 | 36 | 61 |
| Withdrew: Met withdrawal criteria | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 43 | 41 | 46 | 35 |
| Withdrew: Death | 2 | 1 | 1 | 0 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.
| Unitless | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936. | 0.29 (0.05 to 1.68) | 0.50 (0.10 to 2.50) | 0.29 (0.05 to 1.70) | NA (NA to NA) |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.
| Unitless | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936. | 0.29 (0.05 to 1.70) | 0.51 (0.10 to 2.51) | 0.50 (0.10 to 2.48) | NA (NA to NA) |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.
| Unitless | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Time to MACE Until the End of Study NCT01574703. | 0.39 (0.12 to 1.27) | 1.09 (0.42 to 2.83) | 0.75 (0.26 to 2.13) | NA (NA to NA) |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).
| percentage of participants | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936. | 0.05 | 0.10 | 0.05 | 0.20 |
This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.
| percentage of participants | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936. | 0.25 | 0.20 | 0.10 | 0.25 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.
| percentage of participants | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936. | 0.05 | 0.10 | 0.10 | 0.20 |
This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.
| percentage of participants | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936. | 0.25 | 0.20 | 0.15 | 0.35 |
This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.
| percentage of participants | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Incidence of MACE Assessed Until End of Study NCT01574703. | 0.15 | 0.45 | 0.30 | 0.40 |
This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.
| percentage of participants | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Incidence of MACE+ Assessed Until End of Study NCT01574703. | 0.50 | 0.75 | 0.49 | 0.60 |
Collected over Adverse events were collected from Week 24 visit of study NCT01456936 until the end of study (i.e. Week 52 or date of discontinuation, as applicable).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 34/1,192 (2.9%) | 165/1,192 (13.8%) |
| Bupropion | — | 39/1,166 (3.3%) | 160/1,166 (13.7%) |
| NRT Patch | — | 43/1,116 (3.9%) | 116/1,116 (10.4%) |
| Placebo | — | 41/1,121 (3.7%) | 143/1,121 (12.8%) |
| Event | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/1192 | 4/1166 | 2/1116 | 1/1121 |
| PneumoniaInfections and infestations | 1/1192 | 0/1166 | 3/1116 | 0/1121 |
| Atrial fibrillationCardiac disorders | 0/1192 | 0/1166 | 2/1116 | 1/1121 |
| Gallbladder disorderHepatobiliary disorders | 0/1192 | 0/1166 | 2/1116 | 0/1121 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/1192 | 1/1166 | 2/1116 | 0/1121 |
| Cardiac failure congestiveCardiac disorders | 0/1192 | 1/1166 | 0/1116 | 2/1121 |
| AppendicitisInfections and infestations | 0/1192 | 1/1166 | 1/1116 | 2/1121 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/1192 | 1/1166 | 1/1116 | 2/1121 |
| Major depressionPsychiatric disorders | 2/1192 | 1/1166 | 0/1116 | 2/1121 |
| SchizophreniaPsychiatric disorders | 0/1192 | 2/1166 | 1/1116 | 2/1121 |
| Event | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 103/1192 | 78/1166 | 69/1116 | 81/1121 |
| Upper respiratory tract infectionInfections and infestations | 63/1192 | 84/1166 | 48/1116 | 63/1121 |
The term Baseline visit refers to the Baseline (Week 0) visit of the parent study NCT01456936. The safety population included all participants who received at least one dose of study drug in NCT01456936 parent study. The below Baseline characteristics (age, gender) are presented for all participants who entered study NCT01574703.
| Age, Continuous(Years) | Varenicline | Bupropion | NRT Patch | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 48.1 ± 12.2 | 47.7 ± 12.5 | 48.3 ± 11.9 | 47.5 ± 12.2 | 47.9 ± 12.2 |
| Gender(Participants) | Varenicline | Bupropion | NRT Patch | Placebo | Total |
|---|---|---|---|---|---|
| Female | 659 | 648 | 623 | 621 | 2551 |
| Male | 533 | 518 | 493 | 500 | 2044 |
Showing the first 100 of 134 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of May 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Varenicline · Bupropion